SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on February 07, 2023 for Aditya Medisales Ltd SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/Institutional Investor Meeting
Buy Sun Pharmaceutical Industries; target of Rs 1175: Prabhudas Lilladher
Prabhudas Lilladher is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1175 in its research report dated February 01, 2023. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Q3 FY23 Earnings Call Transcript
Sun Pharma Q3 profit rises to Rs 2,166 crore; brokerages suggest 'buy' with 16% upside
Earnings before interest, depreciation, tax, and amortisation (EBITDA) came in at Rs 3,004 crore, 15 percent higher from Rs 2,606 crore reported last year. EBITDA margin widened by 30 bps to 26.7 percent on a yearly basis as against 26.4 percent a year ago. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Investor Call Audio Recording
Q3FY23 Investor call audio recording Q3FY23 Quarterly Result Announced for Sun Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries announced Q3FY23 results: Consolidated Q3FY23: Gross sales at Rs 1,11,001 million, growth of 13.1% over Q3FY22. India formulation sales at Rs 33,919 million, up 7.1% over Q3FY22 US formulation sales at US$ 422 million, up 6.3% vs Q3FY22 Global specialty sales at US$ 235 million, including US$12.5 million milestone received in Q3. Ex-milestone, up 21.6% vs Q3FY22. Global specialty sales, ex-milestone, accounted for 16.5% of Q3FY23 overall sales. Emerging Markets formulation sales at US$ 257 million, up 7.7% vs Q3FY22 Rest of World formulation sales at US$ 189 million, up 4.8% vs Q3FY22 R&D; investments at Rs 6,702 million compared to Rs 5,471 million for Q3FY22. EBITDA at Rs 30,037 million, up 15.2% YoY. EBITDA margin for Q3 at 26.7% versus 26.4% for Q3FY22. Net profit for the quarter was at Rs 21,660 million, up by 5.2% over Q3FY22. Adjusted for one-offs in Q3FY22 and Q3FY23, Net profit growth higher than EBITDA growth. Consolidated 9MFY23: Gross sales at Rs 3,25,533 million, growth of 12.1% over same period last year India formulation sales at Rs 1,02,390 million, up 6.0% over same period last year US formulation sales at US$ 1,254 million, up 10.3% vs Q3FY22 Emerging Markets formulation sales at US$ 762 million, up 8.9% vs Q3FY22 Rest of World formulation sales at US$ 560 million, up 1.2% vs Q3FY22 EBITDA at Rs 88,447 million up 9.8% over same period last year, with resulting EBITDA margin of 26.8% Reported Net profit for 9MFY23 was at Rs 64,891 million, up 16.9% YoY. Excluding the exceptional items of 9MFY22, reported net profit was up by 6.6% Dilip Shanghvi, Managing Director of the Company said, “Specialty is expected to continue as a key growth driver for Sun. We are investing to scale up this business, especially in our core therapy areas. The proposed Concert acquisition is a step forward in this direction. Concert’s lead asset, deuroxolitinib has a potentially best-in-class profile in Alopecia Areata, an area of dermatology with high unmet needs. We are excited to offer this new treatment option to dermatologists worldwide. Given our commercial strength, we would be well-positioned to bring this product to market.” Result PDF SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sun Pharma reports Q3FY23 results. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Change in Directorate
With reference to the intimation of Board meeting submitted on January 16, 2023, we wish to inform you that the Meeting of the Board of Directors of the Company was held today i.e. January 31, 2023 which commenced at 10:00 a.m. and ended at 01:20 p.m. The Board has, inter-alia, Noted the retirement of Mr. Kalyanasundaram Subramanian as Whole-time Director effective from February 13, 2023 The term of Mr. Kalyanasundaram Subramanian (DIN: 00179072), Whole-time Director would end on February 13, 2023, and accordingly he shall retire from the Directorship of the Company with effect from that date.